Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Pecan Promotion Board | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the effects of replacing snacks higher in saturated fats and added sugars with pecans on blood sugar control, heart health and diet quality in individuals with prediabetes. Participants will be randomized into one of two groups. Group 1 will consume 1.5 oz of pecans per day in place of normally consumed snacks higher in saturated fat and added sugars for 16 weeks. Group 2 will be asked to continue consuming their current diet for 16 weeks. Measures will be taken to evaluate blood sugar, heart health and dietary intake at the beginning and 16 weeks later.
This is a 16-week randomized controlled trial. Participants will be randomized to either: 1) replace current snacks higher in saturated fat and added sugars with 1.5 oz/day of pecans; 2) continue their habitual diet. At the beginning and the end of the 16-week study period, testing will be conducted.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pecan snacking group | Experimental | Participants will be provided with 1.5 oz/day of pecans and asked to eat these instead of typically consumed snacks higher in saturated fat and added sugars. |
|
| Usual diet | Active Comparator | Participants will be asked to continue consuming their usual diet. To match attention and resources, participants will be provided with a grocery voucher in approximately equivalent value to the pecans. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pecan snacking | Behavioral | Replacement of typically consumed snacks with 1.5 oz/day of pecans |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in HbA1c | HbA1c will be assessed at baseline and 16-weeks and expressed as percentage . The change in HbA1c will be calculated by subtracting the baseline value from the 16 week value and expressed as percentage point change. | 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in fasting glucose | Change in fasting plasma glucose expressed as mg/dL. Change in glucose will be calculated as the mean of the 16 week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values). | 16 weeks |
| Change in mean glucose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kristina Petersen, PhD | Contact | 814-865-7206 | kup63@psu.edu | |
| Stacey Meily | Contact | 814-863-8622 | sas117@psu.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Pennsylvania State University | Recruiting | University Park | Pennsylvania | 16802 | United States |
De-identified individual participant data will be deposited into an open access repository once results from all pre-specified primary and secondary outcomes are published.
The SAP and protocol will be posted on clinicaltrials.gov prior to enrollment commencing.
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Apr 9, 2026 | Apr 14, 2026 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Apr 14, 2026 | Apr 14, 2026 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D011236 | Prediabetic State |
| D002318 | Cardiovascular Diseases |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Usual diet | Other | Continue with usual diet |
|
Change in mean glucose assessed by a continuous glucose monitor (CGM) expressed as mg/dL. Change in mean glucose will be calculated as mean glucose assessed from 7 days of CGM wear at 16 weeks minus mean glucose assessed from 7 days of CGM wear at baseline. |
| 16 weeks |
| Change in mean time in range | Change in mean time in range (glucose 70-140 mg/dL) assessed by a continuous glucose monitor (CGM) expressed as minutes per day. Change in mean time in range will be calculated as mean time in range assessed from 7 days of CGM wear at 16 weeks minus mean time in range assessed from 7 days of CGM wear at baseline. | 16 weeks |
| Change in glycemic variability | Change in mean glycemic variability assessed by a continuous glucose monitor (CGM) expressed as the coefficient of variability. Change in mean glycemic variability will be calculated as mean glycemic variability assessed from 7 days of CGM wear at 16 weeks minus mean glycemic variability assessed from 7 days of CGM wear at baseline. | 16 weeks |
| Change in fasting insulin | Change in fasting serum insulin expressed as micro IU/mL. Change in insulin will be calculated as the mean of the 16 week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values). | 16 weeks |
| Change in homeostatic model of insulin resistance (HOMA-IR) | Homeostatic model of insulin resistance (HOMA-IR) will be calculated from insulin and glucose measured from a fasting blood sample. Calculated as (insulin × glucose) / 22.5. Change in HOMA-IR will be calculated as the mean of the 16 week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values). | 16 weeks |
| Change in the lipoprotein insulin resistance index | The lipoprotein insulin resistance index will be calculated from Nuclear Magnetic Resonance assessed lipoprotein concentrations according to a previously described method: Metab, Syndr. Relat. Disord. 12 (8) (2014) 422-429. Change will be calculated by subtracting the baseline value from the 16 week value. | 16 weeks |
| Change in LDL-Cholesterol | Assessed from fasting blood draw expressed in mg/dL. Change in LDL-cholesterol will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values). | 16 weeks |
| Change in apolipoprotein B | Assessed from fasting blood draw expressed in mg/dL. Change in apolipoprotein B will be calculated by subtracting the baseline value from the 16 week value. | 16 weeks |
| Change in non-HDL cholesterol | Assessed from fasting blood draw expressed in mg/dL. Change in non-HDL cholesterol will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values). | 16 weeks |
| Change in Total Cholesterol | Assessed from fasting blood draw expressed in mg/dL. Change in total cholesterol will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values). | 16 weeks |
| Change in HDL-Cholesterol | Assessed from fasting blood draw expressed in mg/dL. Change in HDL-cholesterol will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values). | 16 weeks |
| Change in Triglycerides | Assessed from fasting blood draw expressed in mg/dL. Change in triglycerides will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values). | 16 weeks |
| Change in C-reactive protein | Assessed from fasting blood draw expressed in mg/L. Change in C-reactive protein will be calculated as the mean of the 16-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values). | 16 weeks |
| Change in Central Systolic and Diastolic Blood Pressure | Central blood pressure measured assessed using a SphymoCor Xcel (Atcor Medical) at baseline & 16 weeks. Change will be calculated by subtracting the baseline value from the end point value. | 16 weeks |
| Change in Peripheral Systolic and Diastolic Blood Pressure | Peripheral blood pressure measured assessed using a SphymoCor Xcel (Atcor Medical) at baseline & 16 weeks. Change will be calculated by subtracting the baseline value from the end point value. | 16 weeks |
| Change in Carotid-Femoral Pulse Wave Velocity | Measured assessed using a SphymoCor Xcel (Atcor Medical) at baseline & 16 weeks. Change will be calculated by subtracting the baseline value from the end point value. | 16 weeks |
| Change in particle size and number of LDL, HDL, triglyceride rich lipoproteins | Measured via Nuclear Magnetic Resonance at baseline and 16 weeks. The change will be calculated by subtracting the baseline value from the 16 week value. | 16 weeks |
| Change in Saturated fat intake | Assessed from 24-hour recalls completed prior to baseline and at 16 weeks. Change in saturated fat will be calculated as saturated fat intake at 16 weeks minus baseline saturated fat intake. | 16 weeks |
| Change in added sugar intake | Assessed from 24-hour recalls completed prior to baseline and at 16 weeks. Change in added sugar intake will be calculated as added sugar intake at 16 weeks minus baseline added sugar intake. | 16 weeks |
| Change in diet quality | Assessed from 24-hour recalls completed prior to baseline and at 16 weeks. Diet quality will be calculated according to the Healthy Eating Index-2020 (HEI). Change in HEI will be calculated as HEI at 16 weeks minus baseline HEI. | 16 weeks |
| D004700 | Endocrine System Diseases |